Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: eye disorder therapeutics - Alcon

X
Drug Profile

Research programme: eye disorder therapeutics - Alcon

Alternative Names: AR 13154; AR-101; AR-13165; AR-13533; AR-202

Latest Information Update: 22 Mar 2023

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Duke University Medical Center
  • Developer Alcon; Ramot at Tel Aviv University
  • Class Eye disorder therapies; Small molecules
  • Mechanism of Action Amyloid beta-protein inhibitors; Janus kinase inhibitors; Norepinephrine plasma membrane transport protein inhibitors; Platelet-derived growth factor beta receptor antagonists; Protein kinase C inhibitors; Rho-associated kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Diabetic retinopathy; Dry age-related macular degeneration; Glaucoma; Neurological disorders

Most Recent Events

  • 20 Mar 2023 GrayBug inc. has merged with CalciMedica to form CalciMedica
  • 28 Nov 2021 No recent reports of development identified for preclinical development in Diabetic-retinopathy in USA
  • 28 Mar 2020 No recent reports of development identified for preclinical development in Dry age-related macular degeneration in USA

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top